

This is a preview of "AAMI TIR40:2018". Click here to purchase the full version from the ANSI store.

# Technical Information Report



## AAMI TIR40: 2018

**PREVIEW COPY**

This is a preview edition of an AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

For a complete copy of this AAMI document, contact AAMI at +1-877-249-8226 or visit [www.aami.org](http://www.aami.org).

Sterilization of health care  
products—Radiation—  
Guidance on dose setting  
utilizing a Modified  
Method 2

This is a preview of "AAMI TIR40:2018". [Click here to purchase the full version from the ANSI store.](#)



## PREVIEW COPY

This is a preview edition of an AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

For a complete copy of this AAMI document, contact AAMI at +1-877-249-8226 or visit [www.aami.org](http://www.aami.org).

AAMI Technical Information Report

AAMI TIR40:2018



# **Sterilization of health care products—Radiation— Guidance on dose setting utilizing a Modified Method 2**

## **PREVIEW COPY**

This is a preview edition of an AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

For a complete copy of this AAMI document, contact AAMI at +1-877-249-8226 or visit [www.aami.org](http://www.aami.org).

Approved 9 January 2018 by  
**Association for the Advancement of Medical Instrumentation**

Registered 31 January 2018 by  
**American National Standards Institute**

**Abstract:** This technical information report describes the approach for establishing a sterilization dose utilizing a modification of the fraction positive, incremental dosing method defined in Method 2 of ANSI/AAMI/ISO 11137-2.

**Keywords:** radiation, dose setting, Modified Method 2

## AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

This document is not an American National Standard, and the material contained herein is not normative in nature.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every 5 years but at least every 10 years. For a TIR, AAMI consults with a technical committee about 5 years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

**CAUTION NOTICE:** This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

For a complete copy of this AAMI document, contact AAMI at  
+1-877-249-8226 or visit [www.aami.org](http://www.aami.org).

Published by

AAMI  
4301 N. Fairfax Drive, Suite 301  
Arlington, VA 22203-1633

[www.aami.org](http://www.aami.org)

© 2018 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at [www.aami.org](http://www.aami.org) or contact AAMI at 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 978-1-57020-694-8

## Contents

Page

Glossary of equivalent standards .....	iv
Committee representation .....	vi
Foreword .....	ix
1 Scope .....	1
1.1 Inclusions .....	1
1.2 Exclusions .....	1
2 Normative References .....	1
3 Abbreviations, terms, and definitions .....	1
4 Modified Method 2—Application for method .....	4
5 Modified Method 2: Dose setting using fraction positive information from incremental dosing to determine an extrapolation factor .....	4
6 Procedure for Modified Method 2A .....	5
6.1 General .....	5
6.2 Stage 1: Select SAL, and obtain samples of product .....	5
6.3 Stage 2: Perform incremental dose experiment .....	5
6.3.1 General .....	5
6.3.2 A and FFP .....	6
6.3.3 $D^*$ .....	7
6.3.4 $CD^*$ batch .....	7
6.4 Stage 3: Perform verification dose experiment .....	7
6.5 Stage 4: Consideration of results .....	8
6.6 Stage 5: Establish sterilization dose .....	8
7 Procedure for Modified Method 2B .....	9
7.1 General .....	9
7.2 Stage 1: Select SAL, and obtain samples of product .....	9
7.3 Stage 2: Perform incremental dose experiment .....	9
7.3.1 General .....	9
7.3.2 A and FFP .....	10
7.3.3 $D^*$ .....	11
7.3.4 $CD^*$ batch .....	11
7.4 Stage 3: Perform verification dose experiment .....	11
7.5 Stage 4: Consideration of results .....	12
7.6 Stage 5: Establish sterilization dose .....	12
8 Auditing sterilization dose .....	12
9 Worked examples .....	13
9.1 General .....	13
9.2 Worked example for Modified Method 2A .....	13
9.2.1 Stage 2: Incremental dose experiment .....	13
9.2.2 Stage 3: Verification dose experiment .....	15
9.2.3 Stage 5: Calculation of sterilization dose .....	16
9.3 Worked example for Modified Method 2B .....	16
9.3.1 Stage 2: Incremental dose experiment .....	16
9.3.2 Stage 3: Verification dose experiment .....	18
9.3.3 Stage 5: Calculation of sterilization dose .....	19
9.4 Worked example for Modified Method 2A with additional dose required .....	19
9.4.1 Stage 2: Incremental dose experiment .....	19
9.4.2 Stage 3: Verification dose experiment .....	22
9.4.3 Stage 5: Calculation of sterilization dose .....	23
Bibliography .....	27

## Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

[www.aami.org/standards/glossary.pdf](http://www.aami.org/standards/glossary.pdf)



## PREVIEW COPY

This is a preview edition of an AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

For a complete copy of this AAMI document, contact AAMI at +1-877-249-8226 or visit [www.aami.org](http://www.aami.org).

## Committee representation

### Association for the Advancement of Medical Instrumentation

#### Radiation Sterilization Working Group

This technical information report (TIR) was developed by the AAMI Radiation Sterilization Working Group under the auspices of the AAMI Sterilization Standards Committee. Working Group approval of the TIR does not necessarily imply that all committee members voted for its approval.

At the time this document was published, the **AAMI Sterilization Standards Committee** had the following members:

*Cochair:* Mike Scholla

*Members:* Brett Anderson, Cochlear Ltd  
Hank Balch, University Health System  
Richard Bancroft, Steris Corporation  
Garry Bassi, CMC Sterilization Ltd  
Stacy Bohl, Boston Scientific Corporation  
Trabue Bryans, BryKor LLC  
Tim Carlson, Becton Dickinson & Company  
Phil Cogdill, Medtronic Inc Campus  
Sean Colwell, WuXi AppTec Inc  
Ramona Conner, Association of Perioperative Registered Nurses  
Lena Cordie, Qualitas Professional Services LLC  
Jackie Daley  
Gordon Ely, MiMedx Group  
Lisa Foster, Aduvo QS & SA Consulting  
Joel Gorski, NAMSA  
Joyce Hansen, Johnson & Johnson  
Clark Houghtling, Cosmed Group Inc  
Sue Klacik, IAHCSMM  
Byron Lambert, Abbott Laboratories  
Michelle Luebke, Baxter Healthcare Corporation  
Patrick McCormick, Bausch & Lomb Inc  
Gerry McDonnell, Johnson & Johnson  
Gerry O'Dell, Gerry O'Dell Consulting  
Adrian Ponce, Verrill LLC  
Janet Prust, 3M Healthcare  
Nancy Rakiewicz, IUVO BioScience  
Mike Scholla, DuPont Protection Solutions  
Joan Spear, B Braun of America Inc  
Sid Wiggs, Wiggs, Sid - 453204  
Bill Young, Sterigenics International  
Roberto Zumbado, Philips

*Alternates:* Jonathan Bull, Johnson & Johnson  
Greg Crego, IUVO BioScience  
Aaron Dement, Sterigenics International  
Jeffrey Marx, Steris Corporation  
Kim Patton, Becton Dickinson & Company  
Christine Render, Cosmed Group Inc  
Mike Sadowski, Baxter Healthcare Corporation  
Sharon Van Wicklin, Association of Perioperative Registered Nurses  
Craig Wallace, 3M Healthcaress

### Radiation sterilization working group

At the time this document was published, the **AAMI Radiation sterilization working group** had the following members:

*Cochairs:* Emily Craven  
Elaine Daniell

*Members:* Keith Anderson, Smiths Medical  
Ed Arscott, NAMSA  
Anne Booth, Booth Scientific Inc  
Carolyn Braithwaite-Nelson, Spectranetics Corporation  
David Brodersen, LexaMed  
Riley Brown, St Jude Medical Inc  
Trabue Bryans, BryKor LLC  
Harry Bushar  
Rob Calabro, AbbVie  
David Cardin, Cook Inc  
Sarah Chamberlain, Accuratus Labs Services  
Denise Cleghorn, Boston Scientific Corporation  
Debbie Cotton, Baxter Healthcare Corporation  
Gary Cranston, Consulting & Technical Services/PCS  
Emily Craven, Mevex Corporation  
Greg Crego, IUVO BioScience  
Elaine Daniell, CR Bard  
Douglas Davie, Sterilization Validation Services  
Darci Diage, Direct Flow Medical Inc  
Dave Dion, Cardinal Health  
Gordon Ely, MiMedx Group  
Trisha Fair, Cantel Inc.  
Francesco Famosi, Arthrex Inc  
William Fitzgerald, Fitzgerald & Associates Ltd  
Lisa Foster, Aduvo QS & SA Consulting  
Matthew Freeman, Terumo BCT  
Rob Grizzle, Terumo BCT  
Doug Harbrecht, Sterility Assurance LLC  
Deborah Havlik, Hospira, a Pfizer company  
Betty Howard, Steris Corporation  
John Legar, Johnson & Johnson  
Jeff Martin, Sterilization and Quality System Consulting LLC  
Patrick McCormick, Bausch & Lomb Inc  
Nicole McLees, 3M Healthcare  
Rusty Mills, GE Healthcare  
Larry Nichols, Company for Individuals  
Gerry O'Dell, Gerry O'Dell Consulting  
Kevin O'Hara, Sterigenics  
Dave Parente, Ecolab  
Kim Patton, Becton Dickinson & Company  
Michelle Peterson, Stryker Instruments Division  
Rudy Pina, Dynatec Scientific Labs Inc  
Keith Reiner, Terumo Americas Corporate  
Jody Rupert, WL Gore & Associates Inc  
Manny Saavedra, Halyard Health  
Harry Shaffer, Sterilization Consulting Services  
Michael Sprague, Ethide Laboratories Inc  
SopheakSrun, Quality Tech Services Inc  
Fenil Sutaria, Medline Industries Inc  
Jill Warren, WuXi AppTec Inc  
Bud Weisman, Fresenius Medical Care  
Pat Weixel, FDA/CDRH



Beverly Whitaker, Indigo Consulting Group LLC  
John Williams, Medtronic  
Martell Winters, Nelson Laboratories LLC  
Roberto Zumbado, Philips

*Alternates:*

Chris Anderson, Johnson & Johnson  
Agnieszka Baczek, Medline Industries Inc  
Curt Bogue, Cook Inc  
MarJean Boyter, Fresenius Medical Care  
Rachel Brewer, IUVO BioScience  
Angela Brightwell, Medtronic  
Allison Diemert, Anthrex Inc  
Brian Drumheller, Brookhaven Medical Inc  
Diane Faivre-Swiat, Cardinal Health  
Mike Graybill, 3M Healthcare  
Fatima Hasanain, Sterigencis  
Nichole Jackson, Ecolab  
Tara Jacobson, St Jude Medical Inc  
Satu King, Spectranetics Corporation  
Chris Kobus, GE Healthcare  
Ezra Koski, Terumo BCT  
Vu Le, Abbott Laboratories  
Elan Lopezcuba, Becton Dickinson & Company  
Connie McChesney, Alcon Laboratories Inc  
Brian McEvoy, Steris Corporation  
Joseph Mello, Ethide Laboratories Inc  
Astrid Merrifield, Boston Scientific Corporation  
Ken Paddock, Baxter Healthcare Corporation  
Dupeh Palmer-Ochieng, FDA/CDRH  
Michelle Pierce, NAMSA  
Robert Reich, LexaMed Ltd  
Beth Ridgeway, Mesa Laboratories Biological Indicator Division  
Mike Schoene, Bausch & Lomb Inc  
Kristen Spiegel, Stryker Instruments Division  
Mara Tafoya, WuXi AppTec Inc  
Wendy Wangsgard, Nelson Laboratories LLC  
Cas Woss, FitzGerald & Associates Ltd

This is a preview of the AAMI guidance document and is intended to allow potential purchasers to evaluate the content of the document before making a purchasing decision.

---

NOTE—Participation by federal agency representatives in the development of this technical information report does not constitute endorsement by the federal government or any of its agencies.

---

## Foreword

This document is intended to be used in conjunction with ANSI/AAMI/ISO 11137, *Sterilization of health care products—Radiation sterilization* (series). This technical information report (TIR) describes dose-setting methods that may be used to establish the sterilization dose in accordance with one of the two approaches specified in 8.2 (Method 2A) or 8.3 (Method 2B) of ANSI/AAMI/ISO 11137-2:2013.

The basis of the dose-setting methods used in Methods 1 and 2 described in ANSI/AAMI/ISO 11137-2 owes much to the ideas first propounded by Tallentire (Tallentire, 1973; Tallentire, Dwyer, and Ley, 1971; Tallentire and Khan, 1978). Subsequent to these publications, standardized protocols were developed (Davis et al., 1981; Davis, Strawderman, and Whitby, 1984), which formed the basis of the dose-setting methods detailed in the AAMI Recommended Practice for Sterilization by Gamma Radiation (AAMI 1984, 1991).

Methods 2A and 2B of ANSI/AAMI/ISO 11137-2 use data derived from the inactivation of the microbial population in its natural state on product items. Using Method 2 can result in a sterilization dose that is significantly less than the sterilization dose established through the use of either Method 1 or Method VD<sub>max</sub>. Thus, for product types that are susceptible to radiation damage, Method 2 could be the most appropriate method of dose establishment. For a Method 2A dose establishment, 640 product items are required, and for a Method 2B dose establishment, 580 are required (see ANSI/AAMI/ISO 11137-2:2013). The method described herein is a modification of Methods 2A and 2B, and uses a reduced number of product items to establish the sterilization dose. Modified Methods 2A and 2B can each be completed with as few as 360 product items.

This TIR contains guidelines that are not intended to be absolute or to apply in all circumstances. One should use judgment in applying the information in this TIR.

As used within the context of this document, “should” indicates that among several possibilities, one is recommended as particularly suitable, without mentioning or excluding others, or that a certain course of action is preferred but not necessarily required, or that (in the negative form) a certain possibility or course of action should be avoided but is not prohibited. “May” is used to indicate that a course of action is permissible within the limits of the technical information report. “Can” is used as a statement of possibility and capability. Finally, “must” is used only to describe “unavoidable” situations, including those mandated by government regulation.

Suggestions for improving this technical information report are invited. Comments and suggested revisions should be sent to AAMI, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

---

NOTE—This foreword does not contain provisions of AAMI TIR40:2018, *Sterilization of health care products—Radiation—Guidance on dose setting utilizing a Modified Method 2*, but it does provide important information about the development and intended use of the document.

---

# Sterilization of health care products—Radiation— Guidance on dose setting utilizing a Modified Method 2

## 1 Scope

### 1.1 Inclusions

This TIR describes a modification to Methods 2A and 2B of ANSI/AAMI/ISO 11137-2 that reduces the number of incremental doses needed to determine the minimum dose required to achieve a predetermined sterility assurance level (SAL).

This method of sterilization dose establishment may be used to meet the product qualification requirements specified in ANSI/AAMI/ISO 11137-2 when product bioburden is low in number or resistance and has demonstrated historical consistency.

### 1.2 Exclusions

This method of sterilization dose establishment is not to be used to meet the product qualification requirements specified in ANSI/AAMI/ISO 11137-2 when the product bioburden has not been evaluated.

## 2 Normative References

The following normative documents contain provisions that, through reference in this text, constitute provisions of this TIR. For dated references, the subsequent amendments to, or revisions of, any of these publications do not apply. However, parties to agreements based on this TIR are encouraged to investigate the possibility of applying the most recent editions of the following normative documents. For undated references, the latest edition of the normative document referred to applies. AAMI maintains a register of currently valid AAMI technical documents.

- a) ANSI/AAMI/ISO 11137-2, *Sterilization of health care products—Radiation—Part 2: Establishing the sterilization dose*.
- b) ANSI/AAMI/ISO 11137-3, *Sterilization of health care products—Radiation—Part 3: Guidance on dosimetric aspects*.

For harmonization and ease of use, portions of the guidance provided in this TIR are written to align with the clauses of ANSI/AAMI/ISO 11137-2.

## 3 Abbreviations, terms, and definitions

For purposes of this document, the terms and definitions given in ANSI/AAMI/ISO 11137-1 and the following apply.

### 3.1 Abbreviated terms

- 3.1.1 **A:** Dose to adjust the median ffp dose downward, to the FFP dose.

[ANSI/AAMI/ISO 11137-2:2013]